Octagon Capital Advisors’s Centessa Pharmaceuticals CNTA Stock Holding History

Octagon Capital Advisors’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$29.8M	Hold	750,000	–	–	3.3%	11
2025 Q4	$18.8M	Sell	750,000 -80,000	-10%	-$2.03M	2.28%	18
2025 Q3	$20.1M	Sell	830,000 -200,000	-19%	-$3.55M	3.05%	13
2025 Q2	$13.5M	Sell	1,030,000 -395,000	-28%	-$5M	2.97%	17
2025 Q1	$20.5M	Sell	1,425,000 -568,052	-29%	-$9.3M	3.97%	6
2024 Q4	$33.4M	Sell	1,993,052 -19,000	-0.9%	-$315K	5.49%	4
2024 Q3	$32.2M	Sell	2,012,052 -333,023	-14%	-$4.08M	5%	6
2024 Q2	$21.2M	Buy	2,345,075 +284,975	+14%	+$2.7M	3.33%	9
2024 Q1	$23.3M	Hold	2,060,100	–	–	2.79%	8
2023 Q4	$16.4M	Buy	2,060,100 +1,584,500	+333%	+$10.6M	2.62%	11
2023 Q3	$3.08M	Buy	475,600 +63,672	+15%	+$436K	0.47%	32
2023 Q2	$2.55M	Buy	411,928 +15,928	+4%	+$75.6K	0.35%	32
2023 Q1	$1.52M	Buy	+396,000	New	+$1.45M	0.22%	34

Other funds holding CNTA

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

IVLAV

Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Octagon Capital Advisors's CNTA Position: Q1 2026 in Review

Octagon Capital Advisors held its Centessa Pharmaceuticals (CNTA) position steady in Q1 2026 at 750,000 shares worth $29.8M. The position accounts for 3.3% of the portfolio, ranked #11.

Octagon Capital Advisors first reported a position in CNTA in Q1 2023 and has held it in 13 quarters since. The position peaked at $33.4M in Q4 2024. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

Octagon Capital Advisors held 750,000 shares of Centessa Pharmaceuticals worth $29.8M as of Q1 2026.
Octagon Capital Advisors left its Centessa Pharmaceuticals share count unchanged in Q1 2026.
Centessa Pharmaceuticals made up 3.3% of Octagon Capital Advisors's portfolio in Q1 2026, its #11 holding.
Octagon Capital Advisors first reported a position in Centessa Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
Octagon Capital Advisors's Centessa Pharmaceuticals position peaked at $33.4M in Q4 2024.
161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Octagon Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.